Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
Wing Leung(KK Women's and Children's Hospital), Dario Campana(National University of Singapore), Ching‐Hon Pui(St. Jude Children's Research Hospital), Ashok Srinivasan(St. Jude Children's Research Hospital), Rupert Handgretinger(STZ eyetrial), Elaine Coustan‐Smith(St. Jude Children's Research Hospital), David Shook(St. Jude Children's Research Hospital), Sima Jeha(St. Jude Children's Research Hospital), Asha Pillai(St. Jude Children's Research Hospital), Jeffrey E. Rubnitz(St. Jude Children's Research Hospital), Hiroto Inaba(St. Jude Children's Research Hospital), Kwan Gan(St. Jude Children's Research Hospital), Mari Dallas(St. Jude Children's Research Hospital), Raul C. Ribeiro(St. Jude Children's Research Hospital), Joseph Laver(St. Jude Children's Research Hospital), John T. Sandlund(St. Jude Children's Research Hospital), Christine Hartford(St. Jude Children's Research Hospital), Jie Yang(St. Jude Children's Research Hospital), Deqing Pei(St. Jude Children's Research Hospital), Brandon M. Triplett(St. Jude Children's Research Hospital)
Cited by 190
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k